Most people hear "AI and robotics" and immediately think software, coding, and cutting edge engineering. But the partnership between Queensland's Advanced Robotics for Manufacturing (ARM) Hub and Australian Medtech company Microbio is achieving something far more powerful - saving lives.
Microbio has created something pretty remarkable: InfectID-BSI, a diagnostic test that can detect 26 different sepsis-causing pathogens directly from blood in under three hours. Sepsis kills millions globally each year, and is especially challenging and dangerous in places where fast, accurate diagnosis is often out of reach. Getting test results accurately and quickly can literally mean the difference between life and death.
The Challenge
Microbio needed to process and interpret vast volumes of complex data from global clinical trial sites in real time to ensure effective trial management. The challenge extended beyond data handling—requiring a transition from a research-focused organisation to a scalable, international AI-driven diagnostic manufacturing enterprise. That's where innovation hubs like the ARM Hub come in, and they're becoming absolutely crucial for getting Australian research out into the world where it can make a real impact.
Since engaging with Microbio in 2023 to develop their automation and data strategy, ARM Hub worked with the company to build a smart, scalable data system using Databricks' AI Lakehouse technology. This approach empowers Microbio's own non-tech staff to dive into their own data analysis and manage clinical trials across different countries. And they can do so safely, without the need for a computer science degree.
Through hands-on workshops, they mapped out Microbio's entire data and AI strategy, creating a clear path for managing trials globally while setting up solid foundations for future growth. Phase 1 of the data infrastructure was completed in May 2025, which is critical for their data collection and validation for the FDA 810K application process, expected to be submitted in Q4 2026. Microbio can now run clinical trials more efficiently, get more accurate results, and handle diverse international datasets without missing a beat.
So what's the impact?
The collaboration is already paying off. Microbio has locked in distribution deals in Asia, signed with Palex Espana in Spain in May of 2025 for their sepsis technology, and are now positioned to move even faster as they expand globally.
"Instead of exporting Australia's medtech talent as raw IP for others to profit from, Microbio is proving how we can lead globally—by turning cutting-edge research into business nous through data-driven trials, continuous data-led service innovation, and a lean and productive workforce," said Cori Stewart, ARM Hub CEO.
Following their invitation to apply for ARM Hub and MTP Connect's BASA Accelerator at its launch in BIO2024, Microbio was awarded funding in December 2024. The project also received competitive matched funding through the ARM Hub Scaleup Manufacturing for Female Founders Accelerator, demonstrating Australia's commitment to supporting innovative healthcare solutions that can save lives worldwide.
